Wednesday, January 26, 2022 10:53:05 AM
Now you are backtracking. You now admit that you have no idea what the numbers are and yet you are warning that the result will be failure. You have called this a scam in the past. You threw out discount numbers that are ridiculous.
I do know the discount based on Aegis' history and it will be less than 8%. Aegis is a buyer here. They did over three months of due diligence and they are investing in the company. Their single digit fee is their downside protection.
I have no doubt that you understand the offering process. What you don't understand AT ALL is this particular offering.
We shall see. Sunshine is a high risk/high reward play. I don't discount the risk here but I do think you are attempting to identify types of risk that don't exist for this stock.
I do know the discount based on Aegis' history and it will be less than 8%. Aegis is a buyer here. They did over three months of due diligence and they are investing in the company. Their single digit fee is their downside protection.
I have no doubt that you understand the offering process. What you don't understand AT ALL is this particular offering.
We shall see. Sunshine is a high risk/high reward play. I don't discount the risk here but I do think you are attempting to identify types of risk that don't exist for this stock.
Recent SBFM News
- Sunshine Biopharma Announces Issuance of U.S. Patent 12,624,066 B2 Covering Novel Coronavirus Treatment Technology • ACCESS Newswire • 05/29/2026 12:00:00 PM
- Sunshine Biopharma Announces Reverse Stock Split to Maintain NASDAQ Listing • ACCESS Newswire • 05/28/2026 01:00:00 PM
- Sunshine Biopharma Receives Canadian Regulatory Approval for Generic Amoxicillin • ACCESS Newswire • 05/21/2026 11:00:00 AM
- Sunshine Biopharma Inc. Announces Closing of up to $18.0 Million Public Offering • ACCESS Newswire • 05/19/2026 04:05:00 PM
- Sunshine Biopharma Inc. Announces Pricing of $6.0 Million Public Offering • ACCESS Newswire • 05/18/2026 04:15:00 PM
- Sunshine Biopharma Reports Fiscal 2025 Revenue of $36.3 Million, a 4.1% Increase Over Prior Year • ACCESS Newswire • 04/06/2026 12:30:00 PM
- Sunshine Biopharma Gains FDA-Equivalent Clearance in Canada for Domperidone to Treat Cancer-related Nausea • ACCESS Newswire • 10/28/2025 11:45:00 AM
- Sunshine Biopharma Launches STD, Acne and Lyme Disease Therapy Doxycycline • ACCESS Newswire • 10/20/2025 11:45:00 AM
- Sunshine Biopharma Launches Cholesterol Fighting Medicine Pravastatin • ACCESS Newswire • 10/16/2025 11:45:00 AM
- Sunshine Biopharma Allocates $5 Million for Investment in Bitcoin as Strategic Reserve Asset to Enhance Treasury Resilience • ACCESS Newswire • 10/14/2025 11:00:00 AM
- Sunshine Biopharma and University of Arizona Develop a Potent New Series of Protease Inhibitors for Treatment of SARS Coronavirus Infections • ACCESS Newswire • 10/09/2025 12:00:00 PM
